The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. - Tzavara,ET.; Davis,RJ.; Perry,KW.; Li,X.; Salhoff,C.; Bymaster,FP. (Br J Pharmacol, 2003)